COMPANY
Immunexpress
Immunexpress is a privately-owned group of companies developing and commercializing molecular diagnostics to aid clinicians in managing patients with, or suspected of, sepsis through analysis of molecular blood biomarkers from a patient’s immune system (the ‘host response’). Immunexpress and Sepsis Alliance collaborate on educational webinar programs focused on the challenges of diganosing sepsis. From company website Source · Oct 12, 2026
Timeline
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05469048 | Near Patient Molecular Testing in Sepsis | Not listed | Completed | Mar 12, 2020 | May 31, 2021 (actual) |
| NCT02127502 | VENUS: Septic Gene Expression Using SeptiCyte | Not listed | Completed | 2014-04 | 2016-08 (actual) |
| NCT02704871 | The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS | Not listed | Terminated | 2015-06 | 2016-04 (actual) |